The earnings call highlights a successful fiscal year 2025 with record revenue, a return to profitability, and strategic developments like data licensing and new service platforms. However, the fourth quarter showed some weaknesses with a decline in revenue and gross margin. Despite these challenges, the overall sentiment is positive, bolstered by a strong cash position and strategic growth initiatives.

Company Guidance

During the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call, the company reported a significant turnaround with a 14% increase in total revenue to $57 million, up from $50.2 million the previous year. This growth was driven by a 4% rise in research services revenue to $52.3 million and a $4.7 million contribution from data licensing deals. The company's adjusted EBITDA swung to a positive $7.1 million from a loss of $3.9 million in fiscal 2024, aided by disciplined cost execution and high-margin data revenue. Despite a weaker fourth quarter with $12.1 million in revenue and a GAAP operating loss of $2 million, Champions Oncology maintained a gross margin of 41% and ended the year with $9.8 million in cash. The company launched a new radiopharmaceutical services platform and emphasized strategic investments in their data business, anticipating continued growth in fiscal 2026.

Record Revenue Growth

Champions Oncology reported a record total revenue of $57 million for fiscal year 2025, representing a 14% increase from the previous year.

Return to Profitability

The company returned to profitability with an adjusted EBITDA of $7.1 million, a significant improvement from the adjusted EBITDA loss of $3.9 million in fiscal 2024.

Successful Data Licensing Deals

Champions Oncology closed its inaugural data licensing deal in Q3 and several smaller transactions in the recent quarter, contributing $4.7 million to revenue.

Launch of Radiopharmaceutical Services Platform

The company successfully launched a radiopharmaceutical services platform, enhancing its offerings with integrated workflows and collaborations with pharma and biotech partners.

Strong Cash Position

The company ended the year with $9.8 million in cash, up from $2.6 million the previous year, and remains debt-free.

Improved Gross Margins

Gross margin expanded to 50%, up from 42% last year, driven by high-margin data revenue and operational efficiencies.

Champions Oncology (CSBR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSBR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 10, 2025	2026 (Q1)	-0.01 / -	0.11	―	―	―
Jul 23, 2025	2025 (Q4)	-0.20 / -0.07	0.01	-800.00% (-0.08)	―
Mar 11, 2025	2025 (Q3)	-0.01 / 0.36	-0.16	325.00% (+0.52)	―
Dec 11, 2024	2025 (Q2)	0.01 / 0.05	-0.15	133.33% (+0.20)	―
Sep 11, 2024	2025 (Q1)	-0.03 / 0.11	-0.16	168.75% (+0.27)	―
Jul 18, 2024	2024 (Q4)	-0.16 / 0.01	-0.17	105.88% (+0.18)	―
Mar 12, 2024	2024 (Q3)	-0.06 / -0.16	-0.16	0.00% (0.00)	―
Dec 12, 2023	2024 (Q2)	-0.16 / -0.15	0.01	-1600.00% (-0.16)	―
Sep 13, 2023	2024 (Q1)	-0.10 / -0.16	0	―	―
Jul 24, 2023	2023 (Q4)	-0.08 / -0.17	-0.02	-750.00% (-0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSBR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	$7.75	$6.65	-14.19%
Mar 11, 2025	$8.90	$9.79	+10.00%
Dec 11, 2024	$5.84	$5.16	-11.64%
Sep 11, 2024	$4.07	$4.46	+9.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Champions Oncology Inc (CSBR) report earnings?

Champions Oncology Inc (CSBR) is schdueled to report earning on Sep 10, 2025, After Close (Confirmed).

What is Champions Oncology Inc (CSBR) earnings time?

Champions Oncology Inc (CSBR) earnings time is at Sep 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSBR EPS forecast?

CSBR EPS forecast for the fiscal quarter 2026 (Q1) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing